Skip to main content

Table 4 Outcomes of prophylactic micafungin vs. posaconazole during first induction chemotherapy in newly diagnosed AML patients

From: Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy

  Micafungin, n (%) Posaconazole, n (%) P-value
Incidence of fungal infection 2/32 (6.3) 2/39 (5.1) 1.000
 Proven fungal infection 1/32 (3.1) 0  
 Probable fungal infection 0 2/39 (5.1)  
 Possible fungal infection 1/32 (3.1) 0  
Discontinuation of prophylactic antifungal agent 17/32 (53.1) 20/39 (51.3) 0.877
Cause of discontinuation
 Suspected fungal infection 2/32 (6.3) 2/39 (5.1)  
 Prolonged neutropenic fever 13/32 (40.6) 17/39 (43.6)  
 Any adverse event 2/32 (6.3) 0  
 Oral mucositis 0 1/39 (2.6)  
 Antifungal treatment completed 15/32 (46.9) 19/39 (48.7)  
Change to another antifungal agent 16/32 (50.0) 20/39 (51.3) 0.914
Adverse event of prophylactic antifungal agent 2/32 (6.3) 4/39 (10.3) 0.683
 Liver function test abnormality 1/32 (3.1) 4/39 (10.3)  
 Allergic reaction (Grade 2) 1/32 (3.1) 0  
 No adverse event 30/32 (93.8) 35/39 (89.7)  
Cause of mortality during chemotherapy 3/32 (9.4) 2/39 (5.1) 0.652
Fungal infection (proven) 1/32 (3.1) 0  
Respiratory failure (pneumonia, pulmonary edema) 1/32 (3.1) 1/39 (2.6)  
Septic shock 1/32 (3.1) 1/39 (2.6)